FDA Approves New Gonorrhea Treatments Amid Rising Antibiotic Resistance

The FDA has recently approved two new oral medications, gepotidacin and zoliflodacin, to treat gonorrhea. This approval comes shortly after the World Health Organization (WHO) raised concerns about increasing antibiotic resistance globally. These represent the first entirely new treatment options for gonorrhea in over thirty years.

A Growing Threat: Antibiotic Resistance and Gonorrhea

Gonorrhea is a common bacterial sexually transmitted infection (STI), affecting an estimated 82 million people worldwide annually. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates 1.6 million cases each year. A significant challenge in controlling the spread of gonorrhea is that many infected individuals experience no symptoms, unknowingly transmitting the infection to others.

If left untreated, gonorrhea can lead to serious health issues, including infertility in both men and women. The bacterium causing gonorrhea has demonstrated a troubling ability to evolve and resist antibiotics. It has developed resistance to sulfanilamides, penicillins, tetracyclines, and fluoroquinolones. Currently, ceftriaxone, a cephalosporin, is the standard treatment, often paired with azithromycin, though guidelines now often recommend ceftriaxone alone.

Did You Know? Nuzolvence, one of the newly approved drugs, was developed through a partnership between the Global Antibiotic Research and Development Partnership—a nonprofit established by the WHO—and Innoviva Specialty Therapeutics.

New Treatment Options: Blujepa and Nuzolvence

Gepotidacin, marketed as Blujepa, was initially approved in March for treating urinary tract infections. It is administered as eight pills taken in two doses. In a study involving 628 patients, Blujepa demonstrated a 93% cure rate, comparable to the 91% cure rate achieved with the current standard treatment of ceftriaxone and azithromycin. While patients taking Blujepa reported more mild side effects like diarrhea and nausea, these were generally well-tolerated.

Zoliflodacin, to be sold as Nuzolvence, is a single-dose medication that dissolves in water. A study of 930 patients showed a 91% cure rate at the one-week mark with Nuzolvence, compared to 96% with the standard treatment. Nuzolvence was specifically designed to combat antibiotic-resistant gonorrhea, and its use will be limited to treating this infection to help prevent further resistance development.

Expert Insight: The development of these new oral antibiotics represents a significant step forward in addressing the growing challenge of antibiotic resistance in gonorrhea, offering healthcare providers and patients more options for effective treatment.

Edward Hook, MD, an emeritus professor of medicine at University of Alabama and former ASHA board member, emphasized the importance of these new drugs, stating, “It’s been more than 30 years since the FDA approved a new antibiotic for gonorrhea treatment. At a time when antibiotic resistance is increasing worldwide, having new oral antibiotics effective against antibiotic resistant gonorrhea is a great addition to care for persons with an at risk for STIs.”

What Could Happen Next?

The introduction of these new treatments could potentially slow the spread of antibiotic-resistant gonorrhea. However, continued monitoring of resistance patterns will be crucial. It is possible that, over time, the gonorrhea bacterium could evolve resistance to gepotidacin and zoliflodacin as well. Public health efforts focused on prevention, early detection, and responsible antibiotic use will likely remain essential in controlling this STI.

Frequently Asked Questions

What is gonorrhea?

Gonorrhea is one of the most common bacterial sexually transmitted infections (STIs) in the world, with an estimated 82 million cases globally each year.

Why are new treatments for gonorrhea needed?

The bacterium that causes gonorrhea has become resistant to many antibiotics, making treatment more difficult. The new drugs, gepotidacin and zoliflodacin, represent the first new treatment options in over thirty years.

How are the new drugs administered?

Gepotidacin (Blujepa) is taken as eight pills in two doses, while zoliflodacin (Nuzolvence) dissolves in water and is given as a single dose.

As antibiotic resistance continues to be a global health concern, what role do you think individual responsibility and public health initiatives play in combating the spread of STIs?